RenovoRx, Inc. (RNXT) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-0.39 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.40 vs est $-0.39 (missed -2.6%). 2025: actual $-0.32 vs est $-0.28 (missed -16.1%). Analyst accuracy: 92%.
RNXT Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to RenovoRx, Inc. in the past 3 months
EPS Estimates — RNXT
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.40
vs Est –$0.39
▼ 2.5% off
2025
Actual –$0.32
vs Est –$0.28
▼ 13.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RNXT
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.001B
▼ 1,439.5% off
2025
Actual $0.001B
vs Est $0.001B
▼ 16.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
